earnings
confidence high
sentiment positive
materiality 0.85
BeiGene Q2 2024 revenue up 56% to $929M; achieves first non-GAAP operating income
BeOne Medicines Ltd.
2024-Q2 EPS reported
-$0.27
revenue$1,680,818,000
- Total revenue of $929 million, up 56% YoY; BRUKINSA global sales $637M (+107% YoY).
- GAAP operating loss narrowed to $107M from $319M; non-GAAP operating income of $48M (positive inflection point).
- Proposes redomicile from Cayman Islands to Switzerland; opens $800M biologics facility in New Jersey.
- Pipeline: advancing sonrotoclax (BCL2i) and BGB-16673 (BTK degrader); over 15 solid tumor molecules in development.
- BRUKINSA leads BTKi class in U.S. new patient starts across all approved indications.